Chemical Formula: C62H111N11O14

Leucinostatin K

C62H111N11O14 (1233.8311546)

D000890 - Anti-Infective Agents > D023181 - Antimicrobial Cationic Peptides

[gamma-hydroxy-MeLeu]4-[gamma-hydroxy-MeLeu]6-cyclosporin

C62H111N11O14 (1233.8311546)

Leucinostatin_K;_Paecilotoxin_K observed in Leucino A/B standard, annotate with dereplicator

C62H111N11O14 (1233.8311546)

Leucinostatin A, N9-Oxide ; Paecilotoxin K M-H2O+H

C62H111N11O14 (1233.8311546)

Leucinostatin A, N9-Oxide ; Paecilotoxin K observed in Leucinostatin A and B standards

C62H111N11O14 (1233.8311546)

(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-9,24-bis(2-hydroxy-2-methylpropyl)-6,18-diisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone

C62H111N11O14 (1233.8311546)

(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-33-[(1R,2R,4E)-1,6-dihydroxy-2-methylhex-4-en-1-yl]-30-ethyl-9-(2-hydroxy-2-methylpropyl)-6,18,24-triisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone

C62H111N11O14 (1233.8311546)

D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D003524 - Cyclosporins

(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(2R,3R)-5-(2-hydroxyethyl)-3-methyltetrahydrofuran-2-yl]-9-(2-hydroxy-2-methylpropyl)-6,18,24-triisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone

C62H111N11O14 (1233.8311546)

(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-9,18-bis(2-hydroxy-2-methylpropyl)-6,24-diisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone

C62H111N11O14 (1233.8311546)

cyclosporin A metabolite M16

C62H111N11O14 (1233.8311546)

A cyclosporin A derivative that is cyclosporin A in which residues 6 and 9 (both N-methylleucine) have undergone oxidation so a to introduce a hydroxy group at position 4 (the carbon bearing the two methyl groups) in each case.

cyclosporin A metabolite M8

C62H111N11O14 (1233.8311546)

A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol, and in which residue 9 (N-methylleucine) has undergone oxidation so as to introduce a hydroxy group at the carbon bearing the two methyl groups.

cyclosporin A metabolite M10

C62H111N11O14 (1233.8311546)

A cyclosporin A derivative that is cyclosporin A in which residues 4 and 9 (both N-methylleucine) have undergone oxidation so as to introduce a hydroxy group at position 4 (the carbon bearing the two methyl groups) in each case.

cyclosporin A metabolite M26

C62H111N11O14 (1233.8311546)

A cyclosporin A derivative that is cyclosporin A in which residue 9 (N-methylleucine) has been hydroxylated at the carbon bearing the two methyl groups and in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has been hydroxylated at position 8 while the hydroxy group at position 3 has undergone addition to the double bond to give the corresponding oxolane.

(2r,4r,6s)-n-[(1r,2r)-1-[(1-{[(1s)-1-{[(1s)-1-{[1-({1-[(2-{[(2s)-1-(dimethyl-oxo-λ⁵-azanyl)propan-2-yl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]-1-methylethyl}-c-hydroxycarbonimidoyl)-1-methylethyl]-c-hydroxycarbonimidoyl}-3-methylbutyl]-c-hydroxycarbonimidoyl}-3-methylbutyl]-c-hydroxycarbonimidoyl}-1-methylethyl)-c-hydroxycarbonimidoyl]-2-hydroxy-3-methylbutyl]-6-hydroxy-2-({hydroxy[(2s,4s)-4-methyl-1-[(2e,4r)-4-methylhex-2-enoyl]pyrrolidin-2-yl]methylidene}amino)-4-methyl-8-oxodecanimidic acid

C62H111N11O14 (1233.8311546)

n-(1-{[1-({1-[(1-{[1-({1-[(2-{[1-(dimethyl-oxo-λ⁵-azanyl)propan-2-yl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]-1-methylethyl}-c-hydroxycarbonimidoyl)-1-methylethyl]-c-hydroxycarbonimidoyl}-3-methylbutyl)-c-hydroxycarbonimidoyl]-3-methylbutyl}-c-hydroxycarbonimidoyl)-1-methylethyl]-c-hydroxycarbonimidoyl}-2-hydroxy-3-methylbutyl)-6-hydroxy-2-({hydroxy[4-methyl-1-(4-methylhex-2-enoyl)pyrrolidin-2-yl]methylidene}amino)-4-methyl-8-oxodecanimidic acid

C62H111N11O14 (1233.8311546)

n-(1-{[1-({1-[(1-{[1-({1-[(2-{[5-(aminooxy)pentan-2-yl]-c-hydroxycarbonimidoyl}ethyl)-c-hydroxycarbonimidoyl]-1-methylethyl}-c-hydroxycarbonimidoyl)-1-methylethyl]-c-hydroxycarbonimidoyl}-3-methylbutyl)-c-hydroxycarbonimidoyl]-3-methylbutyl}-c-hydroxycarbonimidoyl)-1-methylethyl]-c-hydroxycarbonimidoyl}-2-hydroxy-3-methylbutyl)-6-hydroxy-2-{[hydroxy({4-methyl-1-[(2e,4r)-4-methylhex-2-enoyl]pyrrolidin-2-yl})methylidene]amino}-4-methyl-8-oxodecanimidic acid

C62H111N11O14 (1233.8311546)